EUmergency! GSK merges EU and emerging markets businesses amid sales slump
This article was originally published in Scrip
GlaxoSmithKline's second quarter pharmaceuticals and vaccines sales were down by 6% to £1.67 billion in the US. In Europe, turnover dropped 8% to £1.24 billion, a performance that has prompted GSK to combine its European and Emerging Markets business units under a single commercial structure. Significantly perhaps, the combined unit will be led by Abbas Hussain who is currently president of Emerging Markets and Asia Pacific.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.